PD-L1 and epithelial-mesenchymal transition in circulating tumor cells from non-small cell lung cancer patients: A molecular shield to evade immune system?

References

• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12:252-64; PMID:22437870; https://doi.org/10.1038/nrc3239
   PubMed Web of Science ®Google Scholar
• Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy. Mol Cancer Ther 2015; 14:847-56; PMID:25695955; https://doi.org/10.1158/1535-7163.MCT-14-0983
   PubMed Web of Science ®Google Scholar
• Nicolazzo C, Raimondi C, Mancini ML, Caponnetto S, Gradilone A, Gandini O, Mastromartino M, Del Bene G, Prete A, Longo F et al. Monitoring PD-L1 positive circulating tumor cells in non-small cell lung cancer patients treated with the PD-1 inhibitor nivolumab. Sci Rep 2016; 6:31726; PMID:27553175; https://doi.org/10.1038/srep31726
   PubMed Web of Science ®Google Scholar
• Alsuliman A, Colak D, Al-Harazi O, Fitwi H, Tulbah A, Al-Tweigeri T, Al-Alwan M, Ghebeh H. Bidirectional crosstalk between PD-L1 expression and epithelial to mesenchymal transition: Significance in claudin-low breast cancer cells. Mol Cancer 2015; 14:149; PMID:26245467; https://doi.org/10.1186/s12943-015-0421-2
   PubMed Web of Science ®Google Scholar
• Carpino G, Cardinale V, Gentile R, Onori P, Semeraro R, Franchitto A, Wang Y, Bosco D, Iossa A, Napoletano C et al. Evidence for multipotent endodermal stem/progenitor cell populations in human gallbladder. J Hepatol 2014; 60:1194-202; PMID:24530598; https://doi.org/10.1016/j.jhep.2014.01.026
   PubMed Web of Science ®Google Scholar
• Onori P, Wise C, Gaudio E, Franchitto A, Francis H, Carpino G, Lee V, Lam I, Miller T, Dostal DE et al. Secretin inhibits cholangiocarcinoma growth via dysregulation of the cAMP-dependent signaling mechanisms of secretin receptor. Int J Cancer 2010; 127:43-54; PMID:19904746; https://doi.org/10.1002/ijc.25028
   PubMed Web of Science ®Google Scholar
• Yang KR, Mooney SM, Zarif JC, Coffey DS, Taichman RS, Pienta KJ. Niche inheritance: A cooperative pathway to enhance cancer cell fitness through ecosystem engineering. J Cell Biochem 2014; 115:1478-85; PMID:24700698; https://doi.org/10.1002/jcb.24813
   PubMed Web of Science ®Google Scholar
• Casás-Selves M, Degregori J. How cancer shapes evolution, and how evolution shapes cancer. Evolution (N Y) 2011; 4:624-34; PMID:23705033; https://doi.org/10.1007/s12052-011-0373-y
   PubMedGoogle Scholar
• Ferrao PT, Behren A, Anderson RL, Thompson EW. Editorial: Cellular and phenotypic plasticity in cancer. Front Oncol 2015; 5:171; PMID:26301202; https://doi.org/10.3389/fonc.2015.00171
   PubMed Web of Science ®Google Scholar
• Friedl P, Alexander S. Cancer invasion and the microenvironment: Plasticity and reciprocity. Cell 2011; 147:992-1009; PMID:22118458; https://doi.org/10.1016/j.cell.2011.11.016
   PubMed Web of Science ®Google Scholar
• Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011; 331:1565-70; PMID:21436444; https://doi.org/10.1126/science.1203486
   PubMed Web of Science ®Google Scholar
• Terry S, Chouaib S. EMT in immuno-resistance. Oncoscience 2015; 2:841-2; PMID:26682272; https://doi.org/10.18632/oncoscience.226
   PubMedGoogle Scholar
• Chen L, Heymach JV, Qin FX, Gibbons DL. The mutually regulatory loop of epithelial-mesenchymal transition and immunosuppression in cancer progression. Oncoimmunology 2015; 4(5):e1002731; PMID:26155392; https://doi.org/10.1080/2162402X.2014.1002731
   PubMed Web of Science ®Google Scholar
• Chouaib S, Janji B, Tittarelli A, Eggermont A, Thiery JP. Tumor plasticity interferes with anti-tumor immunity. Crit Rev Immunol 2014; 34:91-102; PMID:24940910; https://doi.org/10.1615/CritRevImmunol.2014010183
   PubMed Web of Science ®Google Scholar
• Chen L, Gibbons DL, Goswami S, Cortez MA, Ahn YH, Byers LA, Zhang X, Yi X, Dwyer D, Lin W et al. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun 2014; 5:5241; PMID:25348003; https://doi.org/10.1038/ncomms6241
   PubMed Web of Science ®Google Scholar
• Lou Y, Diao L, Cuentas ER, Denning WL, Chen L, Fan YH, Byers LA, Wang J, Papadimitrakopoulou VA, Behrens C et al. Epithelial-Mesenchymal transition is associated with a distinct tumor microenvironment including elevation of inflammatory signals and multiple immune checkpoints in lung adenocarcinoma. Clin Cancer Res 2016; 22:3630-42; PMID:26851185; https://doi.org/10.1158/1078-0432.CCR-15-1434
   PubMed Web of Science ®Google Scholar
• Datar I, Schalper KA. Epithelial-Mesenchymal transition and immune evasion during lung cancer progression, the chicken or the egg? Clin Cancer Res 2016; 22:3422-4; PMID:27076625; https://doi.org/10.1158/1078-0432.CCR-16-0336
   PubMed Web of Science ®Google Scholar
• Kim S, Koh J, Kim MY, Kwon D, Go H, Kim YA, Jeon YK, Chung DH. PD-L1 expression is associated with epithelial-to-mesenchymal transition in adenocarcinoma of the lung. Hum Pathol 2016; 58:7-14; PMID:27473266; https://doi.org/10.1016/j.humpath.2016.07.007
   PubMed Web of Science ®Google Scholar
• Mazel M, Jacot W, Pantel K, Bartkowiak K, Topart D, Cayrefourcq L, Rossille D, Maudelonde T, Fest T, Alix-Panabières C. Frequent expression of PD-L1 on circulating breast cancer cells. Mol Oncol 2015; 9:1773-82; PMID:26093818; https://doi.org/10.1016/j.molonc.2015.05.009
   PubMed Web of Science ®Google Scholar
• Satelli A, Batth IS, Brownlee Z, Rojas C, Meng QH, Kopetz S, Li S. Potential role of nuclear PD-L1 expression in cell-surface vimentin positive circulating tumor cells as a prognostic marker in cancer patients. Sci Rep 2016; 6:28910; PMID:27363678; https://doi.org/10.1038/srep28910
   PubMed Web of Science ®Google Scholar
• Ghebeh H, Lehe C, Barhoush E, Al-Romaih K, Tulbah A, Al-Alwan M, Hendrayani SF, Manogaran P, Alaiya A, Al-Tweigeri T et al. Doxorubicin downregulates cell surface B7-H1 expression and upregulates its nuclear expression in breast cancer cells: Role of B7-H1 as an anti-apoptotic molecule. Breast Cancer Res 2010; 12(4):R48; PMID:20626886; https://doi.org/10.1186/bcr2605
   PubMed Web of Science ®Google Scholar
• Azuma T, Yao S, Zhu G, Flies AS, Flies SJ, Chen L. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood 2008; 111:3635-43; PMID:18223165; https://doi.org/10.1182/blood-2007-11-123141
   PubMed Web of Science ®Google Scholar